Saturday 17 October 2026
Export LPCN’s income statement to Excel — free account
Lipocine Inc.
LPCN Healthcare Biotechnology
Lipocine Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.0 million, down 82.3% from fiscal 2024. In the quarter to June 2026, revenue fell 69.5%, EPS grew 22.0% and free cash flow fell 60.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.56
0.12
−7.14%
Follow LPCN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
13.40 | 27.12 | 22.14 | 3.57 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(6.95) | (24.05) | (14.99) | (5.17) | |
P/B ratio |
0.97 | 2.38 | 3.02 | 1.09 | |
Price to Tangible BV |
0.97 | 2.38 | 3.02 | 1.09 | |
EV/Sales |
0.44 | 16.23 | 16.06 | 0.75 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(0.06) | (3.23) | (3.25) | (0.63) | |
EV/FCF |
(0.06) | (3.20) | (3.22) | (0.61) | |
Quick Ratio |
11.39 | 9.87 | 6.36 | 7.90 | |
Current Ratio |
11.48 | 9.99 | 6.68 | 8.25 | |
Net Debt/EBITDA |
8.05 | 6.29 | 5.82 | 4.48 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.07 | 0.09 | 0.10 | 0.24 | |
Operating CF/Net income |
1.15 | 0.61 | 1.23 | 0.94 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,073.86% | 2,315.24% | 233.79% | 2,362.83% | |
Selling, General and Administrative Expense of Revenue |
521.30% | 1,008.79% | 85.86% | 669.98% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
30.56% | 54.77% | 4.63% | 46.51% | |
Graham Net Nets |
1.03 | 0.42 | 0.33 | 0.91 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(73.05%) | (24.53%) | (22.04%) | (35.79%) | |
Free Cash Flow Yield |
(53.67%) | (18.69%) | (22.53%) | (33.96%) | |
Revenue per Share |
0.02 | 0.02 | 0.21 | 0.02 | |
Operating CF per Share |
(0.37) | (0.33) | (0.54) | (0.55) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.37) | (0.33) | (0.54) | (0.55) | |
Cash per Share |
2.83 | 3.64 | 2.74 | 2.80 | |
Shareholders Equity per Share |
2.65 | 3.36 | 2.66 | 2.61 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.65 | 3.36 | 2.66 | 2.61 | |
Free Cash Flow |
(3.03) | (2.26) | (2.92) | (2.99) | |
Working Capital |
21.67 | 22.72 | 14.35 | 14.00 | |
Net Current Asset Value |
21.67 | 22.72 | 14.35 | 14.00 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.21 | 0.20 | 0.69 | 0.10 | |
Average Payables |
0.56 | 0.96 | 0.62 | 0.57 | |
Average Assets |
21.21 | 22.93 | 19.76 | 18.39 | |
Average Common Equity |
19.45 | 21.02 | 17.74 | 16.63 |
Columns are period end dates